Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP FE versus NORETHIN 1 50M 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP FE versus NORETHIN 1 50M 21.
ESTROSTEP FE vs NORETHIN 1/50M-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive